跳至主要内容
临床试验/EUCTR2020-001766-11-FR
EUCTR2020-001766-11-FR进行中(未招募)1 期

osartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE

ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE0 个研究点目标入组 90 人开始时间: 2020年4月15日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Major patient
  • Patient with respiratory distress requiring oxygen support greater than or equal to 6 liters per minute.
  • News-Score greater than 6
  • PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample,
  • Informed Consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 45

排除标准

  • Minor patient,
  • Patient deprived of liberty,
  • Patient's refusal to participate in the study,
  • Patient for whom therapeutic limitation measures have been issued justifying the absence of mechanical ventilation,
  • Patient aged 80 or over,
  • Hypotension justifying treatment with noradrenaline,
  • Acute renal failure with a clearance of less than 60ml / min,
  • Severe liver failure.
  • Intolerance or contraindication to losartan or spironolactone.

研究者

相似试验